1516887-31-2 Usage
Description
(R)-methyl 4-((3R,5R,8S,9S,10R,13R,14S,17R,E)-6-ethylidene-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate is a synthetic chemical compound with a complex molecular structure. It belongs to the class of organic compounds known as steroid esters, characterized by its unique stereochemistry and functional groups. (R)-methyl 4-((3R,5R,8S,9S,10R,13R,14S,17R,E)-6-ethylidene-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate is used in the pharmaceutical industry for various purposes, including potential applications in hormone replacement therapy, anti-inflammatory drugs, or in the treatment of specific medical conditions. However, further research is required to fully understand its properties and potential uses.
Uses
Used in Pharmaceutical Industry:
(R)-methyl 4-((3R,5R,8S,9S,10R,13R,14S,17R,E)-6-ethylidene-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate is used as a pharmaceutical compound for its potential applications in hormone replacement therapy, anti-inflammatory drugs, or in the treatment of specific medical conditions. Its unique molecular structure and stereochemistry may contribute to its therapeutic effects and potential benefits in various medical applications.
Used in Hormone Replacement Therapy:
In the field of hormone replacement therapy, (R)-methyl 4-((3R,5R,8S,9S,10R,13R,14S,17R,E)-6-ethylidene-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate may be used as a hormone analog or precursor to help regulate hormone levels in the body. Its steroidal structure and functional groups may allow it to interact with hormone receptors and modulate hormonal signaling pathways, providing potential therapeutic benefits for conditions related to hormonal imbalances.
Used in Anti-inflammatory Drugs:
(R)-methyl 4-((3R,5R,8S,9S,10R,13R,14S,17R,E)-6-ethylidene-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate may also be used as an anti-inflammatory drug, leveraging its potential to modulate inflammatory pathways and reduce inflammation in the body. Its steroidal nature may enable it to exert anti-inflammatory effects by interacting with specific receptors and signaling pathways, providing relief from inflammation-related symptoms and conditions.
Used in Treatment of Specific Medical Conditions:
Furthermore, (R)-methyl 4-((3R,5R,8S,9S,10R,13R,14S,17R,E)-6-ethylidene-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate may have potential applications in the treatment of specific medical conditions that can benefit from its unique molecular properties. Its ability to interact with various biological targets and modulate signaling pathways may contribute to its therapeutic effects in addressing particular health issues, although further research is needed to fully explore and validate these applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1516887-31-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,1,6,8,8 and 7 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1516887-31:
(9*1)+(8*5)+(7*1)+(6*6)+(5*8)+(4*8)+(3*7)+(2*3)+(1*1)=192
192 % 10 = 2
So 1516887-31-2 is a valid CAS Registry Number.
1516887-31-2Relevant articles and documents
Preparation method of obeticholic acid impurities
-
Paragraph 0059; 0070-0071, (2020/08/02)
The invention discloses a preparation method of obeticholic acid impurities, relates to a synthesis method of five impurities of obeticholic acid, and has important significance for synthesizing high-quality obeticholic acid. (E)-3 [beta]-hydroxy-6-ethylene-7-keto-5[ beta]-cholestane-24-acid (D), 3 [alpha], 7 [alpha]-dihydroxy-6 [beta]-ethyl-5 [beta]-cholestane-24-acid (F), 3 [alpha], 7 [beta]-dihydroxy-6 [beta]-ethyl-5 [beta]-cholestane-24-acid (G), 3 [alpha]-(3 [alpha], 7 [alpha]-dihydroxy-6 [alpha]-ethyl-5 [beta]-cholestane-24-acyloxy)-7 [alpha]-hydroxy-6 [alpha]-ethyl-5 [beta]-cholestane-24-acid (I) and 3-keto-7 [alpha]-hydroxy-6 [alpha]-ethyl-5 [beta]-cholestane-24-acid (L) are mainly researched.
Compound for treating metabolic diseases as well as preparation method and application thereof
-
Paragraph 0170; 0180-0182, (2019/07/04)
The invention provides a compound for treating metabolic diseases, the compound has a structure represented by formula (I) or formula (II), or a racemate, a stereoisomer, a geometric isomer, a tautomer, a solvate, a hydrate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The compounds provided by the invention are FXR and/or TGR5 receptor activators, and the compounds havethe activity of activating FXR and/or TGR5 receptors, and can be used for preparing medicines for treating chronic liver diseases, metabolic diseases or portal hypertension.
Synthesis method of obeticholic acid and intermediate
-
Paragraph 0022, (2018/05/16)
The invention discloses a synthesis method of obeticholic acid and an intermediate. The method specifically comprises seven steps: an oxidation reaction, an esterification reaction, a protection reaction, an Aldol reaction, hydrogenation reduction, hydrolysis and a carbonyl reduction reaction with raw materials including chenodeoxycholic acid, NBS, concentrated sulfuric acid, methanol, sodium iodide, trimethyl silicon chloride, trimethylamine, acetaldehyde, boron trifluoride diethyl etherate, palladium on carbon, hydrogen, NaOH and NaBH4. The synthesis method of obeticholic acid and the intermediate is high in yield, low in cost, environmentally friendly, easy to operate and suitable for industrialization.
